Frontiers in Oncology最新文献

{"title":"Case Report: Laparoscopic resection of a tumor in the right posterior lobe of the liver in a patient with situs inversus totalis.","authors":"Bin Yang, Xin Luo, Genjun Mao","doi":"10.3389/fonc.2025.1513584","DOIUrl":"https://doi.org/10.3389/fonc.2025.1513584","url":null,"abstract":"<p><strong>Background: </strong>Liver cancer poses a major health burden worldwide. Therefore, surgical resection is an important treatment option for patients with liver cancer. In situs inversus totalis (SIT), a rare genetic condition, organs such as the heart, liver, spleen, and stomach are unpaired in the chest and abdominal cavity and their positions are opposite their usual positions.</p><p><strong>Case presentation: </strong>We report a case of SIT with a tumor in the right posterior lobe of the liver in a 70-year-old man. This patient was successfully treated with laparoscopic resection.</p><p><strong>Conclusions: </strong>This case emphasizes that laparoscopic hepatectomy, comprising comprehensive preoperative preparation and fine intraoperative cooperation, is safe and feasible in patients with SIT.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1513584"},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Dihydroartemisinin suppresses the tumorigenesis and cycle progression of colorectal cancer by targeting CDK1/CCNB1/PLK1 signaling.","authors":"","doi":"10.3389/fonc.2025.1591122","DOIUrl":"https://doi.org/10.3389/fonc.2025.1591122","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3389/fonc.2021.768879.].</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1591122"},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11976731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of PDZD11 in hepatocellular carcinoma: prognostic value and diagnostic potential in combination with AFP.","authors":"Yiyun Ni, Bin Liu, Weizhen Zhang, Yilin Pang, Yaling Tian, Qingsong Lv, Shengwen Shi, Yang Zheng, Huihui Fan","doi":"10.3389/fonc.2025.1533865","DOIUrl":"https://doi.org/10.3389/fonc.2025.1533865","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most prevalent liver cancer, with a 5-year survival rate below 20% and an average survival time of 3-6 months. Identifying new biomarkers is crucial for early diagnosis and prognosis. The function of PDZ domain protein 11 (PDZD11) in HCC remains unclear.</p><p><strong>Methods: </strong>In this study, PDZD11 was investigated as a potential biomarker for HCC using bioinformatic analysis of the TCGA and ICGC datasets. Furthermore, we assessed the potential of serum PDZD11 as a clinical diagnostic marker by enrolling a cohort comprising 78 HCC patients and 62 healthy controls (HC) using the ELISA analysis and combining its expression with common tumor markers.</p><p><strong>Results: </strong>Our research found significantly higher PDZD11 mRNA expression in HCC tissues compared to tumor-adjacent tissues (<i>p</i> < 0.001), which was associated with lower overall survival (OS) rates (<i>p</i> < 0.01). Multivariate evaluation methods established PDZD11 as a standalone predictor of prognosis. A nomogram incorporating PDZD11 expression and clinicopathological factors predicted OS rates for HCC patients over various years. Patients with HCC exhibited notably elevated serum PDZD11 levels compared to HC, with these levels rising further in advanced disease stages and deteriorating performance status (PS). ROC analysis showed high diagnostic accuracy when PDZD11 is combined with AFP (AUC = 0.958).</p><p><strong>Conclusion: </strong>PDZD11 is more sensitive than AFP in assessing HCC prognosis. In conclusion, PDZD11 is a promising supplementary biomarker for HCC diagnosis and prognosis alongside AFP.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1533865"},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To explore the risk factors of lymphovascular invasion in patients with upper tract urothelial carcinoma and construct a prediction model.","authors":"Qinghui Li, Pengtao Wei, Yanjie Kang, Xiaohui Li, Han Zhang, Jinhui Yang, Jiantao Sun","doi":"10.3389/fonc.2025.1568774","DOIUrl":"https://doi.org/10.3389/fonc.2025.1568774","url":null,"abstract":"<p><strong>Background and objective: </strong>To explore the risk factors and construct a prediction model of the lymphovascular invasion (LVI) in patients with upper tract urothelial carcinoma (UTUC).</p><p><strong>Methods: </strong>Clinical data of 143 UTUC patients treated in our hospital during Jan. 2010 and Dec. 2022 were retrospectively analyzed. The patients were divided into LVI positive group and LVI negative group according to the postoperative lymphovascular conditions. Kaplan-Meier method was used to evaluate the overall survival (OS) and cancer-specific survival (CSS) of the two groups, and the survival curve was drawn. The correlation between LVI and inclusion indexes was analyzed using univariate and ultivariate. A prediction model was established and receiver operating characteristic (ROC) curve was drawn to analyze the diagnostic value.</p><p><strong>Results: </strong>The median survival time of LVI positive patients was 78 months (95%CI 44.47-111.53), lower than the 90months (95%CI 72.77-107.23) for LVI negative patients, and the 5-year OS of LVI positive patients was 53.0%, lower than that of LVI negative patients (79.6%). The difference was statistically significant (P=0.005). The 5-year CSS of LVI positive patients was 57.0%, lower than that of LVI negative patients (85.7%, P=0.009). The results of univariate analysis showed that there were statistically significant differences between the two groups (P < 0.05) in exfoliation cytology (P=0.044), hydronephrosis (P=0.015), preoperative fibrinogen level (P=0.003), lymph node status (P=0.014), pathological stage (P=0.001) and grade (P=0.047). Multivariate Logistic regression analysis showed that hydronephrosis (P=0.022), pathological stage (P < 0.001), lymph node status (P=0.025) and fibrinogen level (P=0.019) were independent factors influencing the occurrence of lymphovascular invasion, and the combination of four indexes above was better than any single index. the ROC curve showed that the area under the curve (AUC) of postoperative LVI was the largest when combined with the four predictors, and the AUC was 0.833 (95%CI 0.759-0.907). When the Youden index was 0.594, the sensitivity was 81.1%, and the specificity was 78.3%.</p><p><strong>Conclusion: </strong>Lymphovascular invasion is related to hydronephrosis, pathological stage, lymph node condition and fibrinogen level. Patients with preoperative hydronephrosis, high pathological stage, lymph node metastasis and high fibrinogen level were at higher risk of lymphovascular invasion.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1568774"},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A bibliometric analysis of nasopharyngeal carcinoma radiomics: trends and insights.","authors":"Muling Deng, Yuhao Lin, Linghui Yan, Chuanben Chen, Zhaodong Fei, Jianming Ding","doi":"10.3389/fonc.2025.1506778","DOIUrl":"https://doi.org/10.3389/fonc.2025.1506778","url":null,"abstract":"<p><strong>Background: </strong>Nasopharyngeal carcinoma (NPC) is a malignant tumor characterized by distinct geographic and pathological features. Enhancing diagnostic accuracy and timeliness in NPC is crucial for clinical implications. Radiomics has demonstrated significant potential in the clinical management of NPC. Nonetheless, a paucity of bibliometric studies has systematically examined the existing literature in th is domain. The objective of this study was to assess the current landscape and project future trends in NPC research.</p><p><strong>Methods: </strong>This study conducted a search on English-language literature concerning the application of radiomics within the field of nasopharyngeal carcinoma (NPC) research from January 2015 to July 1, 2024, utilizing the Web of Science Core Collection (WoSCC) database. Bibliometric and visual analyses were performed using VOSviewer and CiteSpace software on publications related to countries/regions, authors, journals, references, and keywords.</p><p><strong>Results: </strong>A total of 311 documents were retrieved, yielding 229 eligible documents after screening, comprising 209 articles and 20 reviews. Annual publications showed an upward trend, while citations revealed a generally declining trend. Notably, China contributed the most publications (n=175). Tian Jie and Dong Di each published 13 papers, and Zhang B was the most frequently co-cited author. Frontiers in Oncology published the most articles (n=25), and the International Journal of Radiation Oncology Biology Physics had the highest citation count (n=331). Sun Yat-sen University led institutional publications (n=39). The radiomics research in NPC focuses on survival prediction, texture analysis, and distant metastasis, and may guide future research directions.</p><p><strong>Conclusion: </strong>The application of radiomics in NRC is growing annually, as indicated by bibliometric analysis. Radiomics has enhanced the precision of preoperative diagnosis, prediction, and prognosis in NRC. Bibliometric findings offer insights into radiomics research trends. However, creating extensive NPC datasets and bridging the research-to-clinical gap pose significant challenges. Future research should focus on these areas to advance the development.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1506778"},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report.","authors":"Xiaoqing Li, Suhua Ma, Qing She, Zirong Liu, Yanan Liu, Yanjing Kuang, Xiaozhun Huang, Zhengyin Zhan","doi":"10.3389/fonc.2025.1505596","DOIUrl":"https://doi.org/10.3389/fonc.2025.1505596","url":null,"abstract":"<p><p>Adjuvant lenvatinib in combination with transarterial chemoembolization (TACE) has demonstrated prolonged disease-free survival in hepatocellular carcinoma patients at high risk of recurrence post-resection. Here, we present the case of a 68-year-old woman who developed serious side effects including pemphigus erythematosus (PE) linked to lenvatinib usage. Initially treated for breast cancer with radical surgery in April 2018 followed by adjuvant therapy, she was later diagnosed with liver cancer, initially mistaken for metastatic breast cancer to the liver. Although systemic treatment for advanced breast cancer was received, the tumor continued to progress and required partial removal of the liver after final evaluation. Subsequent pathology revealed hepatocellular carcinoma combined with risk factors for recurrence, prompting adjuvant therapy with TACE and oral lenvatinib. After three weeks of lenvatinib administration, the patient developed a skin rash diagnosed as PE through skin pathology. Treatment involved oral methylprednisolone, intravenous human immune globulin, and supportive care, resulting in a cure within a month. This unique case highlights the importance of further research not only on lenvatinib but also on monitoring and managing adverse reactions associated with targeted drugs to optimize patient safety and treatment outcomes.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1505596"},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a novel <i>NRF1</i>::<i>PDGFRA</i> fusion in myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.","authors":"Jialong Liu, Yaqing Feng, Yanfang Zhang, Yingnan Xiao, Xi Liu, Tingting Xiao, Junyan Zou, Kai Fan, Lisha Lu, Xiaoxia Yang, Jinying Gong","doi":"10.3389/fonc.2025.1552928","DOIUrl":"https://doi.org/10.3389/fonc.2025.1552928","url":null,"abstract":"<p><p>A novel fusion gene <i>NRF1::PDGFRA</i> was identified in a patient with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK), harboring the chromosome abnormality t(4;7)(q12;q32). This represents the first reported case of the <i>NRF1</i>::<i>PDGFRA</i> fusion gene, and the ninth <i>PDGFRA</i>-associated fusion gene identified in MLN-TK. The fusion event led to the constitutive activation of the PDGFRA kinase, resulting in uncontrolled eosinophil proliferation and potentially contributing to the occurrence of cerebral infarction. Our study indicates treatment with low-dose imatinib effectively alleviates the symptoms associated with <i>NRF1::PDGFRA</i> gene fusion.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1552928"},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of ALK high expression in SCLC: a 9-year cohort analysis.","authors":"Jinhe Xu, Wenting Zhang, Feilai Xie, Chenxi Wang, Feng Cheng, Ruiying Rao, Ying Chen, Lei Zhang, Wen Wen, Zhongquan Zhao, Jialing Yuan, Yuqin Zheng, Zongyang Yu","doi":"10.3389/fonc.2025.1530339","DOIUrl":"https://doi.org/10.3389/fonc.2025.1530339","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to investigate the prognostic value of the abnormal expression of anaplastic lymphoma kinase (ALK) protein in patients with small cell lung cancer (SCLC) based on 9-year data from our center.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted to assess the clinical outcomes of patients with ALK-positive SCLC diagnosed in our hospital over the past 9 years. We used public databases to analyze the expression of ALK in pan-cancer and its prognostic value and analyzed the correlation between ALK and SCLC prognosis-related genes.</p><p><strong>Results: </strong>A total of 685 patients diagnosed with SCLC underwent ALK testing, and 59 patients were identified to have abnormal expression of the ALK protein, with 10 cases showing strong expression, 14 cases displaying moderate expression, and 35 cases exhibiting weak expression. The median age of the ALK-positive cohort was 64 years (range: 58-70 years), 91.5% (54/59) were male, 61.0% (36/59) were smokers, and the median overall survival (mOS) was 7.0 months (95% CI: 4.5-9.5 months). Within this cohort, the mOS for the ALK (+) subgroup was 4.0 months (95% CI: 2.9-5.1 months), the mOS for the ALK (++) subgroup was 10.0 months (95% CI: 4.9-15.1 months), and the mOS for the ALK (+++) subgroup was 12.0 months (95% CI: 7.4-16.6 months). Kaplan-Meier revealed that the mOS of the ALK_Low group was significantly worse than that of the ALK_High group [mOS: 4.0 months (95% CI: 2.9-5.1 months) versus 11.0 months (95% CI: 8.3-13.7 months), <i>p</i> = 0.009]. Following covariate adjustment using a Cox regression model, it was indicated that the level of abnormal expression of the ALK protein was an independent prognostic factor for patients with SCLC (HR: 0.486, 95% CI: 0.271-0.871, <i>p</i> = 0.015).</p><p><strong>Conclusion: </strong>The prognosis for patients with SCLC with strong abnormal expression of the ALK protein was significantly better than those with weak expression.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1530339"},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of a DNA repair-associated radiosensitivity index for predicting radiotherapy efficacy in breast cancer.","authors":"Jianguang Lin, Hainan Yang, Rongfu Huang, Tianwen Xu","doi":"10.3389/fonc.2025.1439516","DOIUrl":"https://doi.org/10.3389/fonc.2025.1439516","url":null,"abstract":"<p><strong>Purpose: </strong>Radiotherapy is a cornerstone of breast cancer (BRCA) treatment. Accurately predicting tumor radiosensitivity is critical for optimizing therapeutic outcomes and personalizing treatment strategies. DNA repair pathways are key determinants of radiotherapy response. Thus, we aimed to develop a novel DNA repair-related radiosensitivity model and to identify potential targets for enhancing radiotherapy efficacy.</p><p><strong>Methods: </strong>A retrospective study was conducted using data from 942 BRCA patients from TCGA database. A radiosensitivity model, comprising a radiosensitivity index, was developed using LASSO regression analysis. Patients were stratified into radiosensitive (RS) and radioresistant (RR) groups based on their radiosensitivity index (RSI). Associations between the RSI, clinicopathological parameters, and PD-L1 status were analyzed. The CIBERSORT and ESTIMATE algorithms were employed to characterize the immune landscape of the tumor microenvironment. The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and pRRophetic platform were used to predict treatment responses. Key genes identified in the radiosensitivity model were further validated using <i>in vitro</i> qRT-PCR experiments.</p><p><strong>Results: </strong>We successfully constructed a radiosensitivity index incorporating 10 DNA repair-related genes. Patients in the RS group exhibited significantly better prognosis compared to the RR group, but this benefit was limited to those receiving radiotherapy. This survival benefit associated with the radiosensitivity signature was absent in patients who did not receive radiotherapy. The RS group displayed a distinct molecular profile characterized by enrichment of TGF-β signaling and protein secretion pathways, potentially contributing to enhanced radiosensitivity. Furthermore, the RS group exhibited increased infiltration of immune cells. Notably, the RS-PD-L1-high subgroup demonstrated the most favorable survival outcomes and highest immune cell infiltration, highlighting their potential responsiveness to immunotherapy. In addition, the RR group exhibited a distinct profile characterized by enrichment of DNA repair pathways and a heightened sensitivity to CDK and HER2 inhibitors. Conversely, this group displayed resistance to DNA-damaging drugs. These findings were supported by <i>in vitro</i> experiments using MCF-7 and radioresistant MCF-7/IR cell lines, confirming differential expression of key radiosensitivity index genes.</p><p><strong>Conclusion: </strong>In conclusion, we established a radiosensitivity model for predicting radiotherapy benefit in breast cancer. Our study reveals a strong association between radiosensitivity, enhanced antitumor immunity, and potential immunotherapy benefit, particularly within the RS-PD-L1-high subgroup.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1439516"},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell sequencing reveals the role of aggrephagy-related patterns in tumor microenvironment, prognosis and immunotherapy in endometrial cancer.","authors":"Yuquan Yuan, Chunyan Ren, Jin Shu, Keyang Zhu, Ganghui Li, Bao Liu, Jianrong Huang, Yinde Huang, Chengzhi Zhao","doi":"10.3389/fonc.2025.1560625","DOIUrl":"https://doi.org/10.3389/fonc.2025.1560625","url":null,"abstract":"<p><strong>Background: </strong>As a type of autophagy, aggrephagy degrades the aggregation of misfolded protein in cells and plays an important role in key genetic events for various cancers. However, aggrephagy functions within the tumor microenvironment (TME) in endometrial cancer (EC) remain to be elucidated.</p><p><strong>Methods: </strong>A total of 36,227 single cells from single-cell RNA-seq data derived from five EC tumor samples were comprehensively analyzed using a nonnegative matrix factorization (NMF) algorithm for 44 aggrephagy-related genes. Bulk RNA-seq cohorts from public repositories were utilized to assess the prognostic value of aggrephagy-related TME clusters and predict immune checkpoint blockade immunotherapeutic response in EC.</p><p><strong>Results: </strong>Fibroblasts, macrophages, CD8+T cells, and lymphatic endothelial cells were categorized into two to five aggrephagy-related subclusters, respectively. CellChat analysis showed that the aggrephagy-related subtypes of TME cells exhibited extensive interactions with tumor epithelial cells, particularly for macrophages. Moreover, aggrephagy regulators may be significantly associated with the pseudotime trajectories of major TME cell types as well as the clinical and biological features of EC. Bulk-seq analysis showed that these aggrephagy-related subclusters had significant predictive value for the survival and immune checkpoint blockade response in EC patients. Notably, immunohistochemical staining results manifested that the TUBA1A+ macrophage subtype was linked to less lymph node metastasis and longer survival, which were consistent with the bioinformatics analysis findings.</p><p><strong>Conclusions: </strong>This study provided a novel view of aggrephagy signaling in the EC tumor microenvironment, and intervention of aggrephagy was expected to improve the survival rate of EC patients.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1560625"},"PeriodicalIF":3.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}